Cytiva and Longitude reveal five major challenges for the industry in new Global Biopharma
Booth No.: R514
- A survey of 1,165 biopharma executives and healthcare policymakers across 20 countries measured ability of industry to respond to global needs in five areas: Supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, and government policy and regulation
- There is a strong correlation between higher performing countries and higher income per capita; United States leads the index overall but Switzerland and China have most resilient supply chains
- First such study to cover wide range of topics and respondents
Global life sciences leader Cytiva, along with the Financial Times’ research arm Longitude, have compiled a global index, ranking the ability of the biopharma industry to respond to five major challenges; in supply chain, talent, research and development, manufacturing, and government policy and regulation.
Respondents answered questions on a scale of 1 to 10 in each of the five areas. The average of all responses resulted in the rating of each country’s biopharma capabilities as well as the strength of the global industry. With an overall index score of 6.6 out of 10, the industry looks vulnerable – and has scope to improve across a number of critical areas. In the overall index, the United States ranks first, with a 7.12 score. Switzerland and the UK follow closely.
Russia, China and India are leading in the lower-middle income and upper-middle-income economy countries1, despite having large populations and lower GNI per capita than some of the other countries in this group. However, the index also highlights a clear divide between high-income vs upper-middle-income and lower-middle-income economies. The upper-middle-income and lower-middle-income economies tend to score lower on the index: this indicates that they have less resilient biopharma industries, which creates a significant risk in terms of global access to vital medications.
Emmanuel Ligner, President and CEO, Cytiva, says: “As a partner to global biopharma companies, we wanted to offer this overview of where the industry is performing well, and where there are some pain points. The data is built by listening to customers and key players, and gives us insight into major concerns. With this data, we’ll have even more fruitful conversations and be better prepared to work with customers and stakeholders to address industry-wide challenges.”
Kiran Mazumdar-Shaw, founder and chairperson of Biocon, says: “Biopharma has a huge role to play in the future of medicine, and many of the medicines that we are developing now will be game-changing. But developing blockbuster drugs shouldn’t be about making a billion dollars – it should be about serving a billion patients. That’s when we will have global equity in healthcare.”
Bubble chart: Index scores by Gross National Income per capita.
Bar chart with pillar scores: how far the industry is from best practice in each of the pillars, and summarises what a score of 10 would mean for biopharma.
The index was built from 1,165 survey respondents across 20 countries (95% pharma and biopharma executives and 5% healthcare policymakers), in addition to in-depth interviews with eight experts from biopharma and healthcare policymaking.
Hannah Freegard, Managing Editor at Longitude, a Financial Times company, said: “2020 revealed some uncomfortable truths about a sector that has become a globalized system of production, trade and distribution.”
In-depth look into the five areas
- Supply Chain resilience: 47% of executives say that their country is moderately or highly dependent on the import of drugs. Shortages tend to be more common in countries with a lower GNI per capita, and COVID-19 has exacerbated existing issues around drug insecurity.
- Talent pool: Sourcing talent is a major challenge – compounded by rising costs and inflexible labor regulations. More than half of executives say that the cost of digital, manufacturing and R&D talent has increased in their country in recent years.
- R&D ecosystem: Nearly half of executives believe that both traditional pharma and biopharma firms have a widespread culture of cooperation and open innovation with other sectors (44% for each); however, this drops significantly when looking from the perspective of academic institutions (32%) and government think tanks (27%), among others. This suggests that some areas of the industry lack a culture of open innovation.
- Manufacturing agility: Domestic pharma firms are not ready to fully meet the needs of their own populations. If required, on average countries would be able to fulfill about 75% of the domestic need for insulin and vaccines, but this drops to about 58% for biologics.
- Government policy and regulation: Governments are pursuing policies that support domestic pharma manufacturing, but they must go further to improve funding for start-ups and intellectual property rights.
1Using the World Bank country classifications, based on gross national income per capita
Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit cytiva.com for more.
More Exhibitor's Press Release
- GoldenBiotech HOCENA Granted Compassionate Use for Treatment of Covid-19 Patients GOLDEN BIOTECHNOLOGY CORP. / 2021-07-27
- Covid-19:GoldenBiotech to address at Bio Asia Conference for New Drug GOLDEN BIOTECHNOLOGY CORP. / 2021-07-27
- Psychobiotic PS128 consumption shows benefits to Parkinson's symptoms in new clinical study BENED BIOMEDICAL CO., LTD. / 2021-07-23
- FDA Approval received of CAMCEVI(R); For the Treatment of Advanced Prostate Cancer FORESEE PHARMACEUTICALS CO., LTD. / 2021-07-22
- 2021傑出生技產業獎11家得主出爐 生達、明達抱金質獎 GLOBAL BIO & INVESTMENT MONTHLY / 2021-07-21
- 全球2020生技投資攀高峰! 台灣生技607億台幣創新高 GLOBAL BIO & INVESTMENT MONTHLY / 2021-07-21
- 試管嬰兒補助放寬 奎克生技進軍生殖醫學 亞洲生技線上展 基因檢測受矚目 QUARK BIOSCIENCES TAIWAN, INC. / 2021-07-21
- [AstraZeneca] 生醫界年度盛事「2020國際生醫智能加速器計畫」決選出爐數位醫療、生醫研發同台角逐最終8強脫穎而出將躍國際舞台 BRITISH OFFICE TAIPEI / 2021-07-21
- [AstraZeneca] 攜手Slush 舉辦「醫療照護大未來」線上新創活動 BRITISH OFFICE TAIPEI / 2021-07-21
- [AstraZeneca] 多元包容開啟創新動能 臺灣阿斯特捷利康榮獲2021亞太區傑出雇主 BRITISH OFFICE TAIPEI / 2021-07-21
- [AstraZeneca] 2020聯合國世界糖尿病日 向糖尿病第一線護理人員致敬 醫護齊籲「控糖護健康 e起衛心腎」 BRITISH OFFICE TAIPEI / 2021-07-21
- [AstraZeneca] 健康肺氣喘卓越計劃」第一階段成果發表 全國400家診所加入計劃 嘉惠34,000名氣喘病患 BRITISH OFFICE TAIPEI / 2021-07-21
- A New Era of Interdisciplinary Efforts in New Agriculture: Grand Opening of AgriTech Pavilion COUNCIL OF AGRICULTURE, EXECUTIVE YUAN / 2021-07-20
- 【Review of COVID-19】 MITEK LAB CO., LTD. / 2021-07-20
- The demand for quick screening reagents has greatly increased, IVD materials are supplied ! MITEK LAB CO., LTD. / 2021-07-20
- In 2021, the legal norms of cell therapy in Taiwan gradually opened up MITEK LAB CO., LTD. / 2021-07-20
- A case for additive manufacturing ADDITIVE DESIGN IN SURGICAL SOLUTIONS (ADEISS) INC. / 2021-07-20
- Veterinarians 3D-Printed Part of a Skull for a Dog With Cancer ADDITIVE DESIGN IN SURGICAL SOLUTIONS (ADEISS) INC. / 2021-07-20
- London researchers revamping jawbone surgery with 3D printing technology ADDITIVE DESIGN IN SURGICAL SOLUTIONS (ADEISS) INC. / 2021-07-20
- NYCU GLORIA show eHealth Capabilities through Industrial-Academic-Research-Medical Collaborations NATIONAL YANG MING CHIAO TUNG UNIVERSITY (CENTER FOR INDUSTRY-ACADEMIA COLLABORATION (CIAC) OF NYCU / GLORIA) / 2021-07-19